Although several pharmacological agents already approved by the FDA for other diseases are known to inhibit Panx1 channels [38], further research is needed to find more selective Panx1 inhibitors and to investigate whether Panx1 inhibition can reduce renal damage in CKD and their potential for the treatment of CKD. The gene discussed is PANX1; the disease is chronic kidney disease.